Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Radio Isotope Therapy of America Excel Diagnostic Imaging Clinics RadioMedix St. Luke's Episcopal Hospital, Texas |
---|---|
Information provided by: | Radio Isotope Therapy of America |
ClinicalTrials.gov Identifier: | NCT00442533 |
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
Condition | Intervention | Phase |
---|---|---|
Neuroendocrine Tumors |
Drug: High Dose Indium-111 pentetreotide (Neuroendomedix) |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | High Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor Expressing Neuroendocrine Neoplasms. |
Estimated Enrollment: | 100 |
Study Start Date: | August 2005 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Christiane Assir | 713-341-3239 | cassir@exceldiagnostics.com |
United States, Texas | |
Excel Diagnostic Imaging Clinics | Recruiting |
Houston, Texas, United States, 77042 | |
St. Lukes Episcopal Hospital | Recruiting |
Houston, Texas, United States, 77225-0269 |
Principal Investigator: | Ebrahim Delpassand, M.D. | RITA Foundation |
Responsible Party: | Rita Foundation ( Ebrahim Delpassand ) |
Study ID Numbers: | 06-2247 |
Study First Received: | March 1, 2007 |
Last Updated: | May 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00442533 |
Health Authority: | United States: Food and Drug Administration |
Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neuroepithelioma Somatostatin Neuroendocrine Tumors |
Neoplasms Neoplasms by Histologic Type Neoplasms, Nerve Tissue |